Metabolon raises $15M after two recent tie-ups

Metabolon, a developer of biochemical profiling technology, has raised $15 million in a new round of financing, the company disclosed earlier this week.

It wasn't immediately clear how Durham, NC-based Metabolon plans to use the funds. The company recently announced a collaboration with Richmond, VA-based Global Genomics Group (G3), focused on biomarkers and drug targets for cardiovascular diseases, according to the Triangle Business Journal.

It also has a recently signed marketing agreement with Bostwick Laboratories of Uniondale, NY, the Business Journal reported. Bostwick is a full-service lab specializing in uropathology and urological cancers such as prostate cancer.

Investors include Fletcher Spaght Ventures, Sevin Rosen Funds and Syngenta Ventures.

Metabolon gets its name from metabolomics, the study of the small-molecule signatures generated by metabolic processes. The company advertises its biochemical profiling platform as useful in a wide range of diagnostics.

- read Metabolon's SEC filing
- more from the Triangle Business Journal

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.